McKesson 2026 Q2 Earnings Net Income Surges 305.2%

McKesson (MCK) delivered a standout performance in fiscal 2026 Q2, reporting $1.16 billion in net income, a 305.2% increase from $287 million in 2025 Q2. Earnings per share (EPS) jumped 376.1% to $8.95, far exceeding the prior-year’s $1.88. Revenue grew 10.1% to $103.15 billion, driven by strong segment performance. The company’s stock price, however, dipped 1.12% in the latest trading day despite the earnings beat, reflecting mixed market sentiment.

Revenue

McKesson’s fiscal 2026 Q2 revenue surged 10.1% to $103.15 billion, with the North American Pharmaceutical segment leading the charge at $86.48 billion. The Oncology & Multispecialty segment contributed $12.04 billion, while Prescription Technology Solutions added $1.38 billion. Medical-Surgical Solutions generated $2.95 billion, and other segments, including corporate, accounted for $302 million. This diversified revenue stream underscores the company’s robust market position across healthcare distribution and technology services.

Earnings/Net Income

McKesson’s EPS soared 376.1% to $8.95 in 2026 Q2, reflecting a dramatic improvement in profitability. Net income surged to $1.16 billion, a 305.2% increase from $287 million in 2025 Q2. These figures highlight the company’s ability to capitalize on operational efficiencies and market demand, marking a significant milestone in its financial trajectory.

Post-Earnings Price Action Review

The strategy of buying McKesson shares on the date of its revenue raise announcement and holding for 30 days delivered moderate performance. The 3-year average absolute return was 14.76%, with a maximum return of 20.89% in 2025 and a minimum of 9.99% in 2023. This indicates consistent but not outstanding performance relative to the broader market.

Additional News

McKesson has expanded its oncology and multispecialty capabilities through recent acquisitions, including PRISM Vision and Core Ventures, which bolster its market reach in specialty pharmaceuticals. CEO Brian Tyler sold 11,930 shares in August, reducing his stake by 74.83%, while CAO Napoleon Rutledge, Jr. also divested shares. The company announced a quarterly dividend of $0.82 per share, yielding 0.4%, reflecting its commitment to shareholder returns. Institutional investors, including Main Street Research LLC and Saudi Central Bank, have increased stakes, signaling confidence in McKesson’s long-term prospects.